Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

I-Mab closes $220mm Series C round

Executive Summary

I-Mab Biopharma raised $220mm in its Series C venture round. Hony Capital led and was joined by Hillhouse Capital, HOPU Investments, CDH Investment, Ally Bridge Group, EDBI, C-Bridge Capital, and Tasly Capital. The company is developing immuno-oncology and immuno-inflammatory disease treatments, and will use the proceeds to support preclinical and clinical development of the over ten projects in its pipeline.
Deal Industry
  • Pharmaceuticals
  • Biotechnology
    • Large Molecule
      • Antibodies
Deal Status
  • Final
Deal Type
  • Financing
    • Venture Financing

Related Companies